MAJOR SHAREHOLDERS 18 18.4 18.6 SHAREHOLDERS’ AGREEMENT LOCK-UP AGREEMENT The pre-IPO shareholders’ agreement was automatical ly In the context of the capital increase by means of a private terminated as of the date of the listing of our shares on Euronext placement on June 27, 2017 (i) the Company’s senior executives Paris. and officers have agreed to a lock-up agreement until July 4, In connection with our initial public offering on Euronext Paris, 2018 inclusive and (ii) the employee shareholders have agreed Bpifrance Participations, Mr. José Sahel, Mr. Bernard Gil ly, to a lock-up agreement until July 9, 2018. The terms of these Novartis Pharma AG, Abingworth Bioventures VI L.P., Versant lock-up agreements are described in Section 5.4.4, “Lock-Up Venture Capital IV, L.P., Versant Side Fund IV, L.P., Vitavest S.à.r.l.Agreements” of the prospectus which received visa n°17-297 and Fonds Biothérapies Innovantes et Maladies Rare, several of our from the AMF on June 23, 2017. major shareholders, have entered into a shareholders’ agreement to organize their relationship as shareholders of our Company. 18.7 PLEDGES ON COMPANY’S SHARES 18.5 We are not aware of any pledge relating to our shares. AGREEMENTS LIKELY TO LEAD TO A CHANGE OF CONTROL To our knowledge, there are no provisions either in the Company’s bylaws or in any internal charter or internal rules that could have the effect of delaying, postponing or preventing a change of control of the Company. GENSIGHT BIOLOGICS – 2017 Registration Document– 179